Mendus AB (publ)
Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of tumor recurrence and established tumors. Its lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia (AML); Phase II CADENCE clinical trial to treat AML; and Phase I ALISON clinical trial for the treatment of ovarian cancers. The com… Read more
Mendus AB (publ) (IMMU) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.139x
Based on the latest financial reports, Mendus AB (publ) (IMMU) has a cash flow conversion efficiency ratio of -0.139x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-81.53 Million) by net assets (Skr585.07 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Mendus AB (publ) - Cash Flow Conversion Efficiency Trend (2010–2025)
This chart illustrates how Mendus AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Mendus AB (publ) Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mendus AB (publ) ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Advancecon Holdings Bhd
KLSE:5281
|
0.102x |
|
Sparc Technologies Ltd
AU:SPN
|
-0.290x |
|
Pharmala Biotech Holdings Inc
OTCQB:MDXXF
|
-0.049x |
|
Aurea SA
PA:AURE
|
0.119x |
|
YD More Investments Ltd
TA:MRIN
|
0.208x |
|
VIP Clothing Limited
NSE:VIPCLOTHNG
|
0.094x |
|
Lammhults Design Group AB (publ)
ST:LAMM-B
|
0.029x |
|
Engenco Ltd
AU:EGN
|
0.101x |
Annual Cash Flow Conversion Efficiency for Mendus AB (publ) (2010–2025)
The table below shows the annual cash flow conversion efficiency of Mendus AB (publ) from 2010 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr585.07 Million | Skr-81.53 Million | -0.139x | -12.85% |
| 2024-12-31 | Skr645.15 Million | Skr-79.67 Million | -0.123x | +46.53% |
| 2023-12-31 | Skr704.73 Million | Skr-162.76 Million | -0.231x | -8.67% |
| 2022-12-31 | Skr514.44 Million | Skr-109.33 Million | -0.213x | -1.12% |
| 2021-12-31 | Skr656.74 Million | Skr-138.03 Million | -0.210x | -145.38% |
| 2020-12-31 | Skr661.09 Million | Skr-56.63 Million | -0.086x | +83.98% |
| 2019-12-31 | Skr272.78 Million | Skr-145.81 Million | -0.535x | -107.36% |
| 2018-12-31 | Skr406.04 Million | Skr-104.67 Million | -0.258x | -5.20% |
| 2017-12-31 | Skr189.56 Million | Skr-46.45 Million | -0.245x | +25.64% |
| 2016-12-31 | Skr102.39 Million | Skr-33.74 Million | -0.330x | -14.00% |
| 2015-12-31 | Skr139.18 Million | Skr-40.23 Million | -0.289x | +53.42% |
| 2014-12-31 | Skr64.63 Million | Skr-40.10 Million | -0.621x | -570.22% |
| 2013-12-31 | Skr100.24 Million | Skr-9.28 Million | -0.093x | +68.12% |
| 2012-12-31 | Skr24.60 Million | Skr-7.15 Million | -0.290x | +31.50% |
| 2011-12-31 | Skr7.63 Million | Skr-3.23 Million | -0.424x | +0.26% |
| 2010-12-31 | Skr3.92 Million | Skr-1.67 Million | -0.425x | -- |